APA

Morabito A., Piccirillo M. C., Falasconi F., De Feo G., Del Giudice A., Bryce J., Di Maio M., De Maio E., Normanno N. & Perrone F. (20090615). Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. : The oncologist.

Chicago

Morabito Alessandro, Piccirillo Maria Carmela, Falasconi Fabiano, De Feo Gianfranco, Del Giudice Antonia, Bryce Jane, Di Maio Massimo, De Maio Ermelinda, Normanno Nicola and Perrone Francesco. 20090615. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. : The oncologist.

Harvard

Morabito A., Piccirillo M. C., Falasconi F., De Feo G., Del Giudice A., Bryce J., Di Maio M., De Maio E., Normanno N. and Perrone F. (20090615). Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. : The oncologist.

MLA

Morabito Alessandro, Piccirillo Maria Carmela, Falasconi Fabiano, De Feo Gianfranco, Del Giudice Antonia, Bryce Jane, Di Maio Massimo, De Maio Ermelinda, Normanno Nicola and Perrone Francesco. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. : The oncologist. 20090615.